Seattle, WA -- (SBWIRE) -- 11/07/2019 -- Increasing population of people aged 60 and above is expected to propel growth of the global sarcopenia treatment market. For instance, according to the World Health Organization, by 2050, the world's population aged 60 years and above is expected reach 2 billion from 900 million in 2015. Major institutes and regulatory bodies are focused on increasing awareness regarding sarcopenia, which is also expected to contribute to market growth. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on symptoms and daily impacts of their condition.
The degenerative loss of skeletal muscle mass, quality, and strength associated with aging is called sarcopenia. The condition can restrict from conducting tasks such as standing up from a chair, lifting 10 pounds or more, or other everyday tasks. After the age of 60 or 70, an individual may witness rapid loss of muscle tissue. The rate of degeneration may vary from person to person and the average rate of loss in muscle mass is 3-8% per 10 years. Decrease in muscle mass, weakness, loss of endurance, trouble in climbing stairs, and poor balance are some of the symptoms of sarcopenia. Although sarcopenia has no approved treatment, proper diet and nutrition may aid in management and treatment of the disease. Consuming nutrients can reduce the rate of muscle loss. Individuals suffering from sarcopenia are recommended to maintain diet that includes proteins, amino acids, creatine, omega 3 acid, vitamin D and B12, and calcium carbonate.
PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/2770
Major players in the market are focused on investing in R&D of drugs and supplements for the treatment of sarcopenia. This in turn is expected to propel growth of the global sarcopenia treatment market over the forecast period. For instance, in February 2016, Nestle announced that it has made a strategic investment for of US$ 42.5 million in Pronutria Biosciences. The investment would allow Pronutria Biosciences to develop a new compound called PN-107, which has the potential to tackle muscle loss caused by aging and prolonged bed rest.
Furthermore, increasing number of people in emerging economies suffering from malnutrition and vitamin deficiency is contributing to growth of the market. Aging may lead to decreased secretion of hormones and increasing vitamin deficiency, which leads to high demand for supplements for the tenement of sarcopenia. Increasing disposable income and healthcare expenditure are also aiding in growth of the global sarcopenia treatment market. For instance, according to the National Health Expenditure Accounts (NHEA), in 2016 the U.S. healthcare spending grew by 4.3%, reaching US$ 3.3 trillion or US$ 10,348 per person.
Request Sample Copy of Industry Experts: https://www.coherentmarketinsights.com/insight/request-sample/2770
On the basis of region, the global sarcopenia treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North Africa is expected to account for the largest market share over the forecast period. The market growth is driven by developed healthcare infrastructure in the economies of the U.S., and Canada. Moreover, increasing government support is also expected to contribute to the market growth in North America.
The market in Europe is expected to account for the second largest share over the forecast period. Key players in the market are focused on adopting product development strategies to expand their product portfolio. For instance, in February 2019, Biophytis SA, a France-based company focused on development of novel therapeutics for age-related diseases, announced three oral and poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research (ICFSR). In this conference, the company presented the details of its lead clinical drug candidate, Sarconeos (BIO 101), that included its history and unique mechanism that targets the MAS receptor for preservation of muscle function in muscle wasting disorder. In addition, the company also presented the clinical trial design of its ongoing SARA Phase 2 study of Sarconeos to treat sarcopenia.
Inquire about Discount on this Report: https://www.coherentmarketinsights.com/insight/request-discount/2770
Major players operating in the sarcopenia treatment market include, Sanofi S.A., Bayer AG, GlaxoSmithKline, Abbott Laboratories, Pfizer Inc., Radius Health Inc., Five Prime Therapeutics, Inc., Nestle S.A., Cadila Healthcare Ltd., and Novartis AG.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com